生物技术公司MiNK Therapeutics, Inc.近日披露了其针对PD-1抑制剂难治性胃食管癌的II期临床试验数据。研究结果显示,该疗法在诱导免疫系统重编程方面展现出潜力,并观察到患者获得持久生存获益的积极信号。
生物技术公司MiNK Therapeutics, Inc.近日披露了其针对PD-1抑制剂难治性胃食管癌的II期临床试验数据。研究结果显示,该疗法在诱导免疫系统重编程方面展现出潜力,并观察到患者获得持久生存获益的积极信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.